Skip to main content
Press release November 16, 2026

Xtant Medical Reports Third Quarter 2026 Financial Results and Announces Board-led Strategic Review Process

Xtant Medical Holdings, Inc. (XTNT)

Xtant Medical Reports Third Quarter 2026 Financial Results and Announces Board-led Strategic Review Process Board reiterates commitment to improving performance and maximizing stockholder value; has been actively involved in a comprehensive review of a broad range of strategic, operational, and financial alternatives. BELGRADE, Mont., November 16, 2026 — Xtant Medical Holdings, Inc. (NYSE American: XTNT), a medical technology company focused on surgical solutions for spinal and other orthopedic conditions, today reported financial and operating results for the third quarter ended September 30, 2026. Third Quarter 2026 Financial Highlights ● Total revenue was $24.3 million for the third quarter of 2026, compared to $33.3 million for the third quarter of 2025 and up 5% from $23.0 million in the second quarter of 2026. The year-over-year decrease primarily reflects the absence of revenue from divested businesses and wound care licensing revenue. ● Biologics revenue was $19.3 million for the third quarter of 2026, up 13% from the third quarter of 2025 and up 11% from the second quarter of 2026, third quarter 2026 revenue includes $2.2 million from sales of HEMOBLAST ® Bellows. “The Board is disappointed with Xtant’s financial performance this quarter, which marks the second consecutive quarter in which our results have not met our guidance. That is unacceptable,” said Stavros Vizirgianakis, Chairman of the Board. “Certain directors, including me, have invested their own capital in Xtant, and the Board includes a representative of our largest stockholder. The Board feels this shortfall as owners and stewards of the Company, not just as directors, and the Board’s interests are directly aligned with stockholders. The Board’s priorities are clear: improve execution, improve financial performance, and maximize stockholder value through the strategic review process. Already we are encouraged by how our core biologics business is gaining momentum both quarter-over-quarter and year-over-year.” The Board’s active strategic review process is evaluating a broad range of potential actions to maximize stockholder value, which may include, among other things, operational and performance improvement initiatives, capital allocation and capital structure alternatives, commercial or strategic partnerships, restructurings, financings, acquisitions, dispositions, business combinations or other transactions. The Board has not set a timetable for completion of the strategic review process, and there can be no assurance that the process will result in any particular action or outcome. The Company does not intend to disclose further developments unless and until the Board approves a specific action or otherwise determines that further disclosure is appropriate or required. Third Quarter 2026 Financial Results Revenue for the third quarter of 2026 was $24.3 million compared to $33.3 million for the third quarter of 2025 and up 5% from $23.0 million in the second quarter of 2026. The year-over-year decrease primarily reflects the absence of $5.4 million of prior-year revenue from the divested non-core Coflex/CoFix assets and international hardware business, and the absence of $5.5 million of prior-year wound care licensing revenue, partially offset by $2.2 million of HEMOBLAST revenue. Biologics revenue was $19.3 million, an increase of 13% from $17.1 million for the third quarter of 2025 and 11% from $17.4 million for the second quarter of 2026. Biologics product revenue excluding HEMOBLAST and products affected by the market for wound care reimbursement, a non-GAAP measure, grew 8% compared to the second quarter of 2026 and 6% compared to the third quarter of 2025. Gross margin for the third quarter of 2026 was 56.3%, compared to 66.1% for the same period in 2025. The decrease primarily reflected a 670-basis-point impact from the cessation of high-margin wound care licensing revenue and a 360-basis-point impact from sales mix. Operating expenses for the third quarter of 2026 were $16.7 million, compared to $19.5 million for the third quarter of 2025. General and administrative expenses decreased to $5.0 million from $7.1 million, due primarily to the divested non-core Coflex/CoFix assets and international hardware business and lower expense under compensation plans. Sales and marketing expenses decreased to $11.2 million from $11.7 million due primarily to savings related to the divestitures and lower consulting fees, partially offset by higher compensation expense from increased sales headcount, including sales personnel hired in connection with the Company’s exclusive U.S. distribution agreement for HEMOBLAST, and by higher independent agent commissions and travel expenses. Net loss for the third quarter of 2026 was $3.6 million, or $0.03 per share, compared to net income of $1.3 million, or $0.01 per diluted share, for the third quarter of 2025. Adjusted EBITDA, a non-GAAP measure, was a loss of $1.5 million for the third quarter of 2026, compared to adjusted EBITDA of $4.5 million for the third quarter of 2025. The Company defines adjusted EBITDA as net income/loss from operations before depreciation, amortization and interest income/expense and provision for income tax/benefit, and as further adjusted to add back in or exclude, as applicable, non-cash compensation, the write-off of the distribution agreement deposit, disposition/ acquisition-related income and expenses, acquisition-related fair value adjustments, unrealized foreign currency translation gain or loss, and separation-related expenses. A calculation and reconciliation of adjusted EBITDA to net income (loss) is included in the financial tables at the end of this release. As of September 30, 2026, the Company had $7.8 million of cash and cash equivalents; $22 million of total indebtedness, consisting of $10.2 million of current and long-term debt and $11.8 million of borrowings under its revolving credit facility; and $2.1 million of availability under its revolving credit facility. As of December 31, 2025, the Company had $17.1 million of cash and cash equivalents; $25.4 million of total indebtedness, consisting of $14.5 million of current and long-term debt and $10.9 million of revolving credit borrowings; and $3.8 million of revolving credit availability. Based on its current operating plan, the Company expects its cash and cash equivalents, and availability under its revolving credit facility, to be sufficient to fund operations for at least the next 12 months. 2026 Financial Guidance Based on year-to-date performance, the Company no longer expects to achieve its previously issued full-year 2026 guidance. While the Board of Directors conducts its strategic review process, the Company is not providing revised full-year 2026 financial guidance. At the same time, as detailed elsewhere in this release, the Board is encouraged by the recent momentum in the Company’s core biologics business and remains committed to scaling this franchise throughout the strategic review process. Conference Call Xtant Medical will not host a conference call or webcast to discuss its third quarter 2026 financial results. About Xtant Medical Holdings, Inc. Xtant Medical’s mission of honoring the gift of donation so that our patients can live as full and complete a life as possible, is the driving force behind our company. Xtant Medical Holdings, Inc. (www.xtantmedical.com) is a medical technology company focused on the design, development, and commercialization of a comprehensive portfolio of orthobiologics serving the chronic and surgical wound care and sports medicine markets, as well as spinal implant systems. Xtant people are dedicated and talented, operating with the highest integrity to serve our customers. The symbols ™ and ® denote trademarks and registered trademarks of Xtant Medical Holdings, Inc. or its affiliates, registered as indicated in the United States, and in other countries. All other trademarks and trade names referred to in this release are the property of their respective owners. Non-GAAP Financial Measures To supplement the Company’s consolidated financial statements prepared in accordance with U.S. generally accepted accounting principles (GAAP), the Company uses certain non-GAAP financial measures in this release, including EBITDA, adjusted EBITDA, EBITDA and adjusted EBITDA as a percentage of total revenue, and biologics product revenue excluding HEMOBLAST and products affected by the market for wound care reimbursement. Reconciliations of these non-GAAP financial measures to the most comparable GAAP measures are included in the tables at the end of this release. The Company’s management believes that the presentation of these measures provides useful information to investors. These measures may assist investors in evaluating the Company’s operations period over period. Management uses the non-GAAP measures in this release internally for evaluation of the performance of the business, including the allocation of resources. Investors should consider non-GAAP financial measures only as a supplement to, not as a substitute for or as superior to, measures of financial performance prepared in accordance with GAAP. Cautionary Statement Regarding Forward-Looking Statements This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements include statements that are predictive in nature, that depend upon or refer to future events or conditions, or that include words such as “intends,” “expects,” “anticipates,” “plans,” “believes,” “estimates,” “projects,” “seeks,” “aims,” “goal,” “strategy,” “continue,” “future,” “will,” “would,” “should,” “could,” “may,” “potential,” “opportunity,” “guidance,” similar expressions or the negative thereof, and the use of future dates. Forward-looking statements in this release include, among others, statements regarding the recent momentum in the Company’s core biologics products business and the Board’s commitment to scaling that business; the Board’s priorities to improve execution, improve financial performance, and maximize stockholder value through the strategic review process; the scope, timing, conduct and potential outcomes of the strategic review process; the Company’s expectation that it will not achieve its previously issued full-year 2026 guidance; the Company’s expectation that its cash and cash equivalents and availability under its revolving credit facility, will be sufficient to fund operations for at least the next 12 months; and the expected timing of the filing of the Company’s Quarterly Report on Form 10-Q. The Company cautions that its forward-looking statements by their nature involve risks and uncertainties, and actual results may differ materially depending on a variety of important factors, including, among others: the Company’s future operating results, financial performance and need for additional capital; the Company’s ability to sustain or increase revenue growth in its biologics business, including the possibility that recent growth trends will not continue; results of the Board’s strategic review process, including the possibility that the process will not result in any strategic alternative, operational change, restructuring, transaction, initiative or other action, or that any action taken will not achieve its anticipated benefits or enhance stockholder value; the timing of the strategic review process and the possibility that it may be suspended, modified or terminated at any time; the Company’s ability to identify, negotiate, finance, obtain any required approvals for and complete any strategic alternative, operational change, transaction, partnership, restructuring or other action on favorable terms or at all, and to implement successfully its strategic priorities to improve execution, improve financial performance, and maximize stockholder value through the strategic review process; risks associated with the strategic review process, including disruption and distraction of management, costs, and effects on employees, agents, customers, suppliers and other business relationships; the absence of financial guidance and the Company’s inability to achieve its previously issued guidance; the Company’s ability to generate operating cash flows and maintain availability under its revolving credit facility; the success of the Dilon distribution arrangement and the HEMOBLAST product and the possibility that the distribution agreement may be terminated and the effect of any such termination on the Company, its business and operating results; the ability of Dilon to continue to manufacture and supply the HEMOBLAST product and the effect of any such non-performance on the Company and its business and operating results; the success of the Company’s expanded field sales force to improve its reach and leverage its contract portfolio and independent agent network; other risks associated with acquisitions and dispositions; possible future impairment charges to long-lived assets and goodwill and write-downs of excess and obsolete inventory; its ability to continue to innovate, develop and introduce new products and the success of those products; its ability to remain competitive; its ability to engage and retain new and existing independent distributors and agents and qualified sales and other personnel and its dependence on key independent agents for a significant portion of its revenue; the effect of inflation, elevated interest rates and other recessionary factors and supply chain disruptions; the effect of product sales mix changes on its financial results; the effect of government and third-party coverage and reimbursement for its products, including the absence of future license revenue resulting from changes in the reimbursement environment; its ability to obtain and maintain regulatory approvals and comply with government regulations; the effect of product liability claims and other litigation to which the Company may be subject, including any litigation relating to the strategic review process; the effect of product recalls and defects; its ability to obtain and protect its intellectual property and proprietary rights and operate without infringing the rights of others; its ability to service its debt and comply with the covenants in its credit agreements, including the minimum liquidity and net revenue covenants, to obtain any needed future amendments or waivers, and to access additional indebtedness or financing on favorable terms or at all, if and when needed; and other factors described in its Annual Report on Form 10-K for the year ended December 31, 2025 filed with the Securities and Exchange Commission (SEC) on March 30, 2026 and subsequent SEC reports, including its Quarterly Report on Form 10-Q for the quarterly period ended September 30, 2026 to be filed with the SEC on or about November 16, 2026. Investors are encouraged to read the Company’s filings with the SEC, available at www.sec.gov, for a discussion of these and other risks and uncertainties. The Company undertakes no obligation to release publicly any revisions to any forward-looking statements to reflect events or circumstances after the date hereof or to reflect the occurrence of unanticipated events, except as required by law. All forward-looking statements attributable to the Company or persons acting on its behalf are expressly qualified in their entirety by this cautionary statement. Investor Relations Contact: Kevin Gardner LifeSci Advisors kgardner@lifesciadvisors.com — Tables Follow — XTANT MEDICAL HOLDINGS, INC. Consolidated Balance Sheets (In thousands, except number of shares and par value) As of September 30, 2026 As of December 31, 2025 (Unaudited) ASSETS Current Assets: Cash and cash equivalents $ 7,793 $ 17,053 Restricted cash 92 275 Trade accounts receivable, net of allowance for credit losses and doubtful accounts of $2,756 and $2,165, respectively 18,823 17,803 Inventories 32,503 30,263 Note receivable — 10,462 Prepaid and other current assets 1,395 2,389 Total current assets 60,606 78,245 Property and equipment, net 5,449 6,202 Right-of-use asset, net 2,738 3,192 Goodwill 6,074 6,074 Intangible assets, net 229 299 Other assets 127 133 Total Assets $ 75,223 $ 94,145 LIABILITIES & STOCKHOLDERS’ EQUITY Current Liabilities: Accounts payable $ 5,364 $ 3,844 Accrued liabilities 7,699 10,626 Current portion of long-term debt 4,770 3,500 Current portion of lease liability 588 622 Current portion of finance lease obligations 19 35 Line of credit 11,833 10,857 Total current liabilities 30,273 29,484 Long-term Liabilities: Lease liability, less current portion 2,248 2,665 Finance lease obligation, less current portion — 12 Long-term debt, plus premium and less issuance costs 5,436 11,026 Other liabilities 7 5 Total Liabilities 37,964 43,192 Commitments and Contingencies Stockholders’ Equity: Preferred stock, $0.000001 par value; 10,000,000 shares authorized; no shares issued and outstanding — — Common stock, $0.000001 par value; 300,000,000 shares authorized; 140,452,061 shares issued and outstanding as of September 30, 2026 and 140,039,557 shares issued and outstanding as of December 31, 2025 — — Additional paid-in capital 307,810 305,439 Accumulated other comprehensive loss (1 ) — Accumulated deficit (270,550 ) (254,486 ) Total Stockholders’ Equity 37,259 50,953 Total Liabilities & Stockholders’ Equity $ 75,223 $ 94,145 XTANT MEDICAL HOLDINGS, INC. Consolidated Statements of Operations (Unaudited, in thousands, except number of shares and per share amounts) Three Months Ended September 30, Nine Months Ended September 30, 2026 2025 2026 2025 Revenue Product revenue $ 24,285 $ 27,772 $ 68,200 $ 87,492 License revenue — 5,483 — 14,078 Total Revenue 24,285 33,255 68,200 101,570 Cost of Sales 10,623 11,263 29,237 35,051 Gross Profit 13,662 21,992 38,963 66,519 Operating Expenses General and administrative 5,013 7,071 17,722 22,082 Sales and marketing 11,181 11,746 29,735 34,566 Research and development 496 634 1,626 1,643 Write-off of distribution agreement deposit — — 5,000 — Total Operating Expenses 16,690 19,451 54,083 58,291 (Loss) Income from Operations (3,028 ) 2,541 (15,120 ) 8,228 Other Expense Interest expense (590 ) (904 ) (1,731 ) (2,953 ) Interest income — — 220 — Unrealized foreign currency transaction (loss) gain (10 ) (56 ) 12 146 Other income (expense) 231 (16 ) 820 (18 ) Total Other Expense (369 ) (976 ) (679 ) (2,825 ) Net (Loss) Income from Operations Before Provision for Income Taxes (3,397 ) 1,565 (15,799 ) 5,403 Provision for Income Taxes Current and Deferred (165 ) (257 ) (265 ) (487 ) Net (Loss) Income $ (3,562 ) $ 1,308 $ (16,064 ) $ 4,916 Net (Loss) Income Per Share: Basic $ (0.03 ) $ 0.01 $ (0.11 ) $ 0.04 Diluted $ (0.03 ) $ 0.01 $ (0.11 ) $ 0.03 Shares used in the computation: Basic 140,363,595 139,712,969 140,228,117 139,366,489 Diluted 140,363,595 150,377,234 140,228,117 149,912,292 XTANT MEDICAL HOLDINGS, INC. Consolidated Statements of Cash Flows (Unaudited, in thousands) Nine Months Ended September 30, 2026 2025 Operating activities: Net (loss) income $ (16,064 ) $ 4,916 Adjustments to reconcile net (loss) income to net cash (used in) provided by operating activities: Depreciation and amortization 1,525 3,404 Loss (gain) on sale of fixed assets — (16 ) Non-cash interest 380 415 Stock-based compensation 2,451 2,165 Provision for reserve on accounts receivable 987 568 Provision for excess and obsolete inventory 2,904 1,318 Write-off of distribution agreement deposit 5,000 — Other 4 68 Changes in operating assets and liabilities: Accounts receivable (2,007 ) (5,639 ) Inventories (4,215 ) (2,789 ) Prepaid and other assets 166 314 Accounts payable 1,519 (1,279 ) Accrued liabilities (2,927 ) 3,721 Net cash (used in) provided by operating activities (10,277 ) 7,166 Investing activities: Purchases of property and equipment (830 ) (1,987 ) Proceeds from sale of fixed assets 129 206 Distribution agreement deposit (5,000 ) — Proceeds from divestitures 10,368 5,000 Net cash provided by investing activities 4,667 3,219 Financing activities: Borrowings on line of credit 51,879 77,573 Repayments on line of credit (50,902 ) (78,385 ) Payments on long-term debt (4,701 ) (5,000 ) Debt issuance costs — (49 ) Payments on financing leases (27 ) (51 ) Payment of taxes from withholding of common stock on settlement of restricted stock units (80 ) (116 ) Net cash used in financing activities (3,831 ) (6,028 ) Effect of exchange rate changes on cash and cash equivalents and restricted cash (2 ) 63 Net change in cash and cash equivalents and restricted cash (9,443 ) 4,420 Cash and cash equivalents and restricted cash at beginning of period 17,328 6,221 Cash and cash equivalents and restricted cash at end of period $ 7,885 $ 10,641 Reconciliation of cash and cash equivalents and restricted cash reported in the condensed consolidated balance sheets Cash and cash equivalents $ 7,793 $ 10,400 Restricted cash 92 241 Total cash and restricted cash reported in condensed consolidated balance sheets $ 7,885 $ 10,641 XTANT MEDICAL HOLDINGS, INC. CALCULATION OF NON-GAAP CONSOLIDATED EBITDA AND ADJUSTED EBITDA (in thousands) Three Months Ended September 30, Nine Months Ended September 30, 2026 2025 2026 2025 Net (Loss) Income $ (3,562 ) $ 1,308 $ (16,064 ) $ 4,916 Depreciation and amortization 483 1,161 1,525 3,404 Interest expense, net 590 904 1,511 2,953 Tax expense 165 257 265 487 Non-GAAP EBITDA (2,324 ) 3,630 (12,763 ) 11,760 Net (Loss) Income/Total Revenue (14.7 )% 3.9 % (23.6 )% 4.8 % Non-GAAP EBITDA/Total Revenue (9.6 )% 10.9 % (18.7 )% 11.6 % NON-GAAP ADJUSTED EBITDA CALCULATION Non-cash compensation 830 641 2,451 2,165 Write-off of distribution agreement deposit — — 5,000 — Divestiture/acquisition-related expenses (94 ) 74 (612 ) 369 Acquisition-related fair value adjustments 37 140 132 311 Unrealized foreign currency translation loss (gain) 10 56 (12 ) (146 ) Separation related expenses 69 — 69 23 Non-GAAP Adjusted EBITDA $ (1,472 ) $ 4,541 $ (5,735 ) $ 14,482 Non-GAAP Adjusted EBITDA/Total Revenue (6.1 )% 13.7 % (8.4 )% 14.3 % XTANT MEDICAL HOLDINGS, INC. RECONCILIATION OF NON-GAAP BIOLOGICS PRODUCT REVENUE GROWTH (in thousands) Three Months Ended September 30, 2026 September 30, 2026 % Increase (Decrease) Total Revenue $ 24,285 $ 23,031 License Revenue — — Hardware Revenue 4,944 5,671 Biologics Revenue 19,341 17,360 Sales related to HEMOBLAST and products affected by the market for wound care reimbursement 2,204 1,518 Biologics product revenue excluding HEMOBLAST and products affected by the market for wound care reimbursement $ 17,137 $ 15,842 8 % Three Months Ended September 30, 2026 September 30, 2025 % Increase (Decrease) Total Revenue $ 24,285 $ 33,255 License Revenue — 5,483 Hardware Revenue 4,944 10,623 Biologics Revenue 19,341 17,149 Sales related to HEMOBLAST and products affected by the market for wound care reimbursement 2,204 935 Biologics product revenue excluding HEMOBLAST and products affected by the market for wound care reimbursement $ 17,137 $ 16,214 6 %
View original release